 |
|
|
|
 |
|
 |
|
TESTIMONIALS |
|
|
|
|
|
|
I am 66 years old. I was diagnosed in June 2007 with prostate cancer and in October 2007, I underwent robotic radical prostatectomy. Prior to the surgery, my virility was ok. After the surgery, it was compromised, but began to get better as of April 2008. In June 2008 however, I was diagnosed with residual prostate cancer and underwent radiation for seven weeks during the summer of 2008. This aggravated situation caused me to have a very serious condition of erectile dysfunction.
To gain an erection, I tried manual and battery operated vacuum constriction devices and found them to be kind of bulky and cumbersome to use and at times embarrassing and frustrating during the operation of getting an erection and maintaining it for the desired time of achieving satisfactory sex.
I spoke to my urologist of my condition and frustration and he referred me to Dr. Eid for consultation. I made my appointment, consulted with Dr. Eid who explained the options to me, the penile implant seemd the best for me. I did the surgery in April 2009. It was very successful. I am performing extremely well in bed, my partner is thrilled and totally satisfied with our sex and so am I. My self-esteem has returned and I feel like a man again.
We are forever grateful to the affable, highly professional and talented Dr. Eid. |
|
| more + |
|
|
|
|
 |
|
 |
|
|
 |
|
 |
|
CONTACT INFORMATION |
|
|
|
|
|
 |
|
J. Francois Eid, M.D.
50 East 69th Street
New York, NY 10021 |
|
|
|
Ph: 212-535-6690 |
|
|
|
Fax: 212-535-7025 |
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
 |
|
 |
|
|
|
|
|
Penile Prosthesis Technology - Advancements and Innovations |
|
|
|
|
 Latest Inflatable Penile Prosthesis (IPP) Innovations:
Updates have been made to the Inflatable Penile Prosthesis (IPP) pumps offered by both American Medical Systems (AMS) and Coloplast (formerly Mentor), as well as to the CX and LGX cylinders offered by AMS. Also, AMS has added an antibiotic coating to its Artificial Urinary Sphincter (AUS).
See details on the Implant Innovations page.
Penile implant technologies have continually improved since their introduction. The following is a history of advancements and innovations in penile prosthesis technology.
|
January 2000:
The Mentor Lock-out™ valve reservoir is introduced to the market.
The Lockout valve is designed to prevent auto-inflation of the penile cylinders. The Lock-out valve has been demonstrated in bench testing to prevent auto-inflation of cylinders despite extensive force on the reservoir or elevated pressure within the reservoir. In preliminary clinical evaluation, the Lock-out valve has significantly diminished the prevalence and severity of auto-inflation. (NOTE: Mentor’s urology business was bought by Coloplast in 2006.)
|
 Late 2000:
Parylene Micro Coating
Parylene Micro Coating is introduced as a feature to enhance the American Medical Systems 700 Series cylinder durability and subsequent longevity. Parylene coating is applied via a vapor deposition process to non-tissue-contacting surfaces. It increases lubricity to the silicone surface, hence reducing friction and wear. The new Parylene coating, a micro-thin (60 millionths of an inch) layer, has been demonstrated in bench testing to add millions of fold and tube wear stress cycles before detectable wear is noted on the silicone surface.
|
May 2001:
AMS introduces the first permanent antibiotic eluting implant (InhibiZone).
 InhibiZone is a formulation of Minocycline Hydrochloride and Rifampin, which is impregnated onto the outer surfaces of the device resulting in a marbled yellow-orange trace or modelled effect. Depending on the size of the penile prosthesis selected, devices are manufactured with a quantifiable amount of minocycline and rifampin. Antibiotics impregnated into the device surface elute from the silicone matrix when exposed to a warm, moist environment, resulting in a localized antibiotic regimen. Concentrations represent less than a common oral or IV dose. The cylinders, reservoir, pump and tubing are all completely treated with the drug eluting technology.
Minocycline and rifampin have been safely used as a surface treatment in indwelling venous and urinary catheters. The scientific platform was transferred to the IPP technology to focus on a proven method to provide broad-spectrum inhibitory activity against gram-positive, gram-negative bacteria (1). Literature shows the combination of minocycline and rifampin to act synergistically to prevent colonization of bacteria and be particularly effective against staphylococcus, the most common cause of IPP infection (2).
The majority of the InhibiZone antibiotic surface treatment elutes from the IPP within the initial 2-3 days post-implant, with the remainder of the drug eluting over the next 2-3 weeks. Thus, the effects of InhibiZone primarily reduce early infections. Expectations of a rifampin and minocycline combination should show a reduction in staphylococcal-based infections, the most common cause (about 70%) of IPP infections. Parylene micro coating to increase cylinder durability is also incorporated into the InhibiZone cylinders. |
May 2002:
Mentor Corporation (now Coloplast) introduces a more anatomical distal cylinder tip to the standard Alpha I cylinders.
(This more anatomical distal tip was introduced with the narrow-base cylinders in May of 1996).
The anatomically shaped distal tip is designed to provide for a better fit and a natural aesthetic result. In addition, the smooth, soft distal tip of the Alpha I is seamlessly integrated into the cylinder bladder. The Narrow-base cylinders prosthesis (introduced in May 1996) was the only pre-connected narrow inflatable device available. Implant base diameter is 3.7mm narrower (with rear tip extenders) than the regular Alpha I implant. The cylinder bladder diameter has also been reduced by 2mm, resulting in an ideal design for fibrotic corpora, re-operations and narrow anatomy. In addition the cylinder base/tubing angle is reduced from 45 degrees to 22.5 degrees, which allows for easier placement into the proximal corpora. The dilation required for placement of this device is only to 10mm. This allows for easier surgeries and decreases the risk of perforation of the tunica albuginea (outer layer of penile erectile chamber). Also the narrow-base cylinder design results in less pronounced folds while in the flaccid state. Finally, the narrow-base cylinder expands to 18mm girth when inflated (same as regular AMS 700 series). |
 August 2002:
The Mentor (now Coloplast) Titan™ Hydrophilic Coating prosthesis is introduced in the US.
This coating is covalently bonded and designed for long-term attachment to the device. This hydrophilic coating is designed to help inhibit bacterial adherence. This technology, when used to coat central venous catheter and hydrocephalus shunts, was effective against staphylococcus (3,4). Animal studies demonstrated sustained inhibition against Staph epidermidis up to three days following implantation (5). This hydrophilic surface allows physicians to maintain their current antibiotic device preparation. When soaked in an antibiotic solution prior to implantation, antibiotic which will coat the device will then be eluted over a time period. In addition, the surface of the cylinders becomes lubricious, which makes it easier to implant the device. |
 July 2004:
AMS introduces the Tactile pump for the 700 series implant.
In addition to its ability to transfer a slightly larger volume of fluid with each squeeze, the pump came with a modified exterior surface for easier inflation. The deflation part of the pump was also increased in size, and sharper edges were added to permit easier localization of the deflation valve and permit better deflation. (For more detail, see Implant Innovations.) |
 January 2006:
AMS introduces the first “Momentary Squeeze” (MS) pump with a one-touch button.
Called the AMS 700MS for “Momentary Squeeze,” it is designed for easier deflation. These features allowed the patient to first press the button, and then squeeze the cylinders to obtain full deflation. Holding the deflation valve while squeezing the cylinders simultaneously was no longer necessary. In addition, the pump had a smaller body, which increased patient comfort, and a lockout valve to resist auto inflation. Finally, palpable ridges were added to the pump to permit easier inflation. (For more detail, see Implant Innovations.) |
July 2008:
Approval of the “One-Touch Release” pump
 Coloplast (previously Mentor) receives approval for the “One-Touch Release” pump that also allowed the patient to squeeze one time only and release to obtain deflation. This is an important development for the Titan model because the deflation was always difficult for patients implanted with the previous model.
Coloplast Titan(r) One-Touch Release (OTR) recently became available in the U.S. Initial Titan OTR implants have been conducted in the U.S., Europe and Canada, with encouraging results. The OTR features a true, one-touch deflation system. The well-defined deflation system, or "Touch Pads" are designed to create a discernible landmark for the patient to quickly and confidently access. The new deflation system helps promote quick, confident training for both the patient & healthcare practitioner, as well as ongoing ease-of-use for the patient and partner. (For more detail, see Implant Innovations.) |
top of page
|
|
|
|
|
|
|
|
|
|
